Thanks for the ping. Mitochondrial health seems indeed essential to neurological health. See from yesterday: Mitochondrial Transport Key to Neurological Health
I’m still taking acarbose from time to time whenever I have a big meal (most likely on social occasions). However, I’m unsure about its potential for neurodegenerative diseases, and I was (positively) surprised to see the Leigh article when it was published. I’m unsure because, contrary to GLP1RAs and SGLT2is that seem to be associated in longitudinal studies and RCTs with lower risks of depression (a pre-symptom of many NDDs), AD, and PD, acarbose (and other α-glucosidase inhibitors) seems to be “neutral” for these conditions:
- Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis 2023: "DPP-4is, α-glucosidase inhibitors and insulin had a neutral effect on risk of dementia, while meglitinides and sulphonylureas were associated with increased risk.”
- Thiazolidinedione use and risk of Parkinson’s disease in patients with type 2 diabetes mellitus 2022
- The Effectiveness of Antidiabetic Drugs in Treating Dementia: A Peek into Pharmacological and Pharmacokinetic Properties 2022: “A nested case–control study by Wium-Andersen et al. found that acarbose was not associated with a lower OR for dementia [18]. A population-based cohort study, using Korean National Health Insurance claims data of new-onset type 2 diabetes patients between 2002 and 2013, found that acarbose monotherapy did not reduce the risk of dementia [48]. Moreover, a retrospective cohort study using the longitudinal reimbursement database of Taiwan’s National Health Insurance (NHI) found that α-glucosidase inhibitor use did not reduce the risk of dementia. The cohort included 15,524 matched pairs of ever- and never-users of acarbose from patients with new-onset type 2 diabetes patients between 1999 and 2006 [49]. These findings suggest that the glucose-lowering effect of antidiabetic drugs is insufficient to exert a beneficial effect on dementia.”
- Evaluation of Metformin on Cognitive Improvement in Patients With Non-dementia Vascular Cognitive Impairment and Abnormal Glucose Metabolism 2018: ”However, there was no obvious improvement in cognitive function in the acarbose-donepezil group.”
Also, most people with NDD have impaired olfactory neurons and acarbose does not seem to help with this whereas GLP1RAs do: Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study 2022
It worked in autonomic failure though so it could help to manage some symptoms of NDDs: Acarbose, an α-Glucosidase Inhibitor, Attenuates Postprandial Hypotension in Autonomic Failure 2007
One caveat to the above: acarbose is mostly used in Asia, so maybe the studies don’t have enough acarbose users in the West or maybe acarbose is more beneficial to Westerners than Asians. I don’t know.
Also, there are two exceptions that found potential neuro benefits:
- Association of cardiovascular disease management drugs with Lewy body dementia: a case–control study 2024: recent paper, great journal and authors but even there exenatide does better than acarbose for DLB, with a way better p-value. SGLTis were not included (too recent?), but I would hope empagliflozin would do even better than exenatide.
- Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone 2020: “In conclusion, reduced risk of dementia associated with acarbose is observed in the female sex and in non-users of metformin.” => It’s a good journal but a single author. I would discount it. (and I’m a male so less relevant for me anyway…)
Let’s see if the Leigh study triggers a renewed interest in acarbose for NDDs, but for now, I would rank it way lower than GLP1RA and SGLT2 for long-term neuroprotection (meaning, in practice, AD and PD).